Sarep­ta li­cens­es next-gen AAV tech from Broad In­sti­tute in deal cov­er­ing five in­di­ca­tions — in­clud­ing Duchenne

Sarep­ta’s re­search agree­ment with the Broad In­sti­tute is tak­ing the next step Mon­day.

The biotech will li­cense a new group of ade­no-as­so­ci­at­ed virus­es from the in­sti­tute for an undis­closed up­front pay­ment and mile­stone promis­es, the pair an­nounced Mon­day morn­ing. Un­der the agree­ment, Sarep­ta will have the rights to five neu­ro­mus­cu­lar and car­diac in­di­ca­tions, in­clud­ing Duchenne mus­cu­lar dy­s­tro­phy, where it’s al­ready well-versed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER